[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629450":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":31,"locations":32,"responsibleParty":50,"collaborators":52,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":31,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":31,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":31,"overallStatus":74,"whyStopped":31,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Liaquat University of Medical & Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lactobacillus crispatus CRP21 (Crispavag®)","EXPERIMENTAL","Participants receive an oral probiotic supplement containing Lactobacillus crispatus CRP21 (Crispavag®) following standard antibiotic treatment for bacterial vaginosis. Participants take one capsule daily for 12 weeks and are followed for an additional 12 weeks to assess recurrence of bacterial vaginosis.",[13],"Dietary Supplement: Lactobacillus crispatus CRP21",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants receive placebo capsules identical in appearance to the probiotic product following standard antibiotic treatment for bacterial vaginosis. Participants take one capsule daily for 12 weeks and are followed for an additional 12 weeks to assess recurrence of bacterial vaginosis.",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Lactobacillus crispatus CRP21","Oral probiotic supplement containing Lactobacillus crispatus CRP21 (Crispavag®, Pharmextracta S.p.A., Italy). Participants take one capsule daily for 12 weeks following standard antibiotic treatment for bacterial vaginosis.",[9],[27],"Crispavag®",{"type":6,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"Matching placebo capsules identical in appearance to the probiotic product, administered orally once daily for 12 weeks following standard antibiotic treatment for bacterial vaginosis.",[15],null,[33],{"facility":34,"status":31,"city":35,"state":36,"zip":31,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of Urbino Carlo Bo","Urbino","Pesaro And Urbino","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],12.63633,43.72621,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":31,"phoneExt":31,"email":49},"Davide Sisti, PhD","CONTACT","davide.sisti@uniurb.it",{"type":51,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[53],{"name":54,"class":6},"University of Urbino \"Carlo Bo\"","100629450","evaluation-of-the-ability-of-lactobacillus-crispatus-crp21-to-reduce-the-incidence-of-recurrent-bacterial-vaginosis-100629450",false,"NCT07474831","Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis","Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Female participants aged 18 to 45 years\n* Diagnosis of recurrent bacterial vaginosis\n* At least three documented episodes of bacterial vaginosis in the previous 12 months\n* Completion of standard antibiotic therapy for bacterial vaginosis before enrollment\n* Willingness to comply with study procedures and follow-up visits\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Current use of systemic antibiotics or antifungal therapy not related to treatment of bacterial vaginosis\n* Known hypersensitivity to probiotic products or study components\n* Presence of other significant gynecological infections requiring treatment\n* Use of vaginal probiotic products within 30 days prior to enrollment\n* Participation in another clinical trial within the previous 30 days","FEMALE","18 Years","45 Years",{"count":66,"type":67},156,"ESTIMATED","INTERVENTIONAL",[70],"NA","Recurrent bacterial vaginosis is a common condition in women of reproductive age and is characterized by a disruption of the normal vaginal microbiota, with a reduction in Lactobacillus species and an overgrowth of anaerobic bacteria such as Gardnerella vaginalis. Recurrence rates after standard antibiotic treatment are high. Lactobacillus crispatus is considered one of the most protective species for maintaining vaginal microbiota balance.\n\nThis multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of a probiotic supplement containing Lactobacillus crispatus CRP21 (Crispavag® capsules) in reducing the incidence of recurrent bacterial vaginosis in women diagnosed with recurrent bacterial vaginosis. After standard antibiotic treatment, participants will be randomly assigned in a 1:1 ratio to receive either the probiotic supplement or a placebo for 12 weeks.\n\nThe primary objective is to evaluate whether supplementation with Lactobacillus crispatus CRP21 reduces the incidence of recurrent bacterial vaginosis episodes compared with placebo. Participants will be followed for a total of 24 weeks, including a 12-week treatment period and a 12-week follow-up period.",[73],"Recurrent Bacterial Vaginosis","NOT_YET_RECRUITING","2026-03-20",{"date":77,"type":78},"2026-03-25","ACTUAL",{"date":80,"type":67},"2026-03-23",{"date":82,"type":67},"2027-04-16",{"name":5,"class":6},1]